Product Information
EFFEXOR XR 150 MG CAPSULE is a brand product labeled by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., priced at $21.6254 per EA under NDC 00008083621. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Oct 20, 1997. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the VENLAFAXINE HYDROCHLORIDE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
150 mg/1
NDC
00008083621
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA020699FDA Approved
10/20/1997
TE Code
AB
On Market Since
11/1/1997
Pharmacological Classes
Price Statistics
The NADAC for EFFEXOR XR 150 MG CAPSULE has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 223.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $21.6254 per EA |
|---|---|
| All-time high | $21.6254 (Aug 19, 2026) |
| All-time low | $6.6869 (Nov 28, 2013) |
| 52-week high | $21.6254 |
| 52-week low | $20.5777 |
| Median price | $16.1750 |
| Average price | $15.3659 |
| Largest weekly change | +9.4% (Jun 8, 2016) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EFFEXOR XR 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for EFFEXOR XR 150 MG CAPSULE, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., is $21.6254 per EA (NDC 00008083621), effective Aug 19, 2026.
How has the price of EFFEXOR XR 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for EFFEXOR XR 150 MG CAPSULE has risen 223.4%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EFFEXOR XR 150 MG CAPSULE?
Since Nov 28, 2013, the NADAC for EFFEXOR XR 150 MG CAPSULE has ranged from a low of $6.6869 (Nov 28, 2013) to a high of $21.6254 (Aug 19, 2026), with a median of $16.1750 per EA.
Are there cheaper alternatives to EFFEXOR XR 150 MG CAPSULE?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VENLAFAXINE HCL ER 150 MG CAP, is $0.1162 per EA — about 99% below EFFEXOR XR 150 MG CAPSULE.
Who manufactures EFFEXOR XR 150 MG CAPSULE?
EFFEXOR XR 150 MG CAPSULE (NDC 00008083621) is labeled by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., and CMS classifies it as a brand product.